Brad Kahl, MD

Medical Oncologist

Primary Academic Title

Professor of Medicine, Division of Oncology Director, Lymphoma Program, Washington University School of Medicine

Clinical Expertise

Hematologic malignancies, lymphoma, chronic lymphocytic leukemia

Research Interest

My interests involve clinical and translational efforts to improve outcomes for lymphoma patients. I am particularly interested in novel agents and testing of those agents in clinical trials. I have led several clinical trials in the Eastern Cooperative Oncology Group and currently serve as Chair of the ECOG Lymphoma Committee.

Education

1994: MD, Tufts University School of Medicine, Boston

Training

1994 - 1998: Resident, internal medicine, University of Wisconsin, Madison
1998 - 2000: Fellow, hematology, University of Wisconsin, Madison

Board Certification

1997: American Board of Internal Medicine
2001, 2011: American Board of Internal Medicine - Hematology

Selected Research Publications

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.

Caimi PF, Ai WZ, Alderuccio JP, [...] Kahl BS, [...] Carlo-Stella C
Haematologica 2024

Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.

Kahl BS, Jegede OA, Peterson C, [...] Williams ME
J Clin Oncol 2024

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.

Cerhan JR, Maurer MJ, Link BK, [...] Kahl BS, [...] Flowers CR
Am J Hematol 2024

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

Fehniger TA, Watkins MP, Ezenwajiaku N, [...] Kahl B, Bartlett NL
Haematologica 2024

Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.

Brown JR, Ghia P, Jurczak W, Kahl BS, [...] Tedeschi A
Haematologica 2024

Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.

Crombie JL, Graff T, Falchi L, [...] Kahl BS, [...] Dickinson M
Blood 2024

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.

Alderuccio JP, Reis IM, Hamadani M, [...] Kahl BS, [...] Moskowitz CH
Clin Cancer Res 2024

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

Qualls DA, Lambert N, Caimi PF, [...] Kahl BS, [...] Salles G
Blood 2023

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.

Vose JM, Fu K, Wang L, [...] Kahl BS, [...] Bi C
J Hematol Oncol 2023

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

Maurer MJ, Casulo C, Larson MC, [...] Kahl BS, [...] Flowers CR
Haematologica 2023

SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma.

Patel D, Kahl B
Clin Lymphoma Myeloma Leuk 2023

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

Patel DA, Wan F, Trinkaus K, [...] Kahl BS
Clin Lymphoma Myeloma Leuk 2023

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

David KA, Sundaram S, Kim SH, [...] Kahl B, Evens AM
Am J Hematol 2023

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.

Alderuccio JP, Reis IM, Koff JL, [...] Kahl BS, [...] Lossos IS
Blood 2023

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.

Desai SH, Spinner MA, David K, [...] Kahl B, [...] Micallef IN
Am J Hematol 2023

View All Publications

Contact Information

Washington University Medical Campus

4921 Parkview Place
Saint Louis, MO 63110
South St. Louis County

5225 Midamerica Plaza
St. Louis, MO 63129

Phone Numbers

Appointments: (314) 747-7222
Toll Free: (800) 600-3606

Request an appointment